50 results about "Miglitol" patented technology

Production of miglina is carried out by providing chiral center by L-phenylalanine. It achieves high efficiency and good optical purity, and to avoid chemical resolution and asymmetric hydrogenation.

The orally disintegrated miglitol tablet for type-II diabetes consists of main medicine and supplementary material, the main medicine miglitol accounts for 5-50 % and is 10-200 mg in each tablet, and supplementary material consists of stuffing 5-30 wt%, disintegrating agent 5-45 wt%, disintegrating assistant 5-30 wt% and fine silica gel powder 0.1-3 wt% or consists of stuffing 5-30 wt%, disintegrating agent 5-45 wt%, disintegrating assistant 5-30 wt%, adhesive 5-15 wt% and lubricant 0.1-3 wt%. The disintegrated miglitol tablet is prepared with the material powder and through direct or wet tabletting. It is easy to take and can make full use of miglitol in treating diabetes effectively to lower the concentration of blood sugar after meal.

The invention relates to a pharmaceutical composition having alpha-glucosidase inhibition activity, wherein the pharmaceutical composition comprises a flavone compound and an alpha-glucosidase inhibitor, the flavone compound is at least one selected from a monomer such as baicalein, quercetin, luteolin, baicalein-7-O-glucoside and catechin, an organic salt of the monomer, and an inorganic salt of the monomer, and the alpha-glucosidase inhibitor is at least one selected from a monomer such as acarbose, voglibose and miglitol, an organic salt of the monomer, and an inorganic salt of the monomer. According to the present invention, the pharmaceutical composition can effectively reduce postprandial blood glucose, can inhibit the activity of alpha-glucosidase adopting starch, maltose and sucrose as substrates, and less uses the alpha-glucosidase inhibitor, such that the efficacy can be improved, the side effect of the alpha-glucosidase inhibitor can be effectively reduced, and hypoglycemia and other problems easily caused by drug combination are effectively solved.

The invention relates to a kind of method for synthesizing midbody N-(2-ethoxyl)-glucosamine of diabetes therapy medicine miglitol alcohol. The existing literature has no synthesizing method recordation of midbody N-(2-ethoxyl)-glucosamine. The reaction steps of the invention are as follows: A) Stuff casting: in autoclave, add D-glucose and ethanolamine according to molar ratio of D-glucose/ethanolamine with 1/1.05-1.10; then add 70-95% alcohols solvent with 5-10 times weight of glucose; and after nitrogen displace, add 5%Pd-CaCO3-1-5%Pb catalyst with 2-10% weight of glucose; inject high purity hydrogen, keep hydrogen pressure to 2-3Mpa, and then intensify the temperature slowly up to reaction temperature; B) Reaction: control reaction temperature in 35-45deg.C, hydrogen pressure in 2-4Mpa, and reaction by 20-24 hours; C) Get white pulverous solid by after-treatment. The invention selects the appropriate catalyst and reasonable hydrogenization technology, so that it can make the reaction condition of glucose and ethanolamine with relatively gentleness, make the reaction easy to proceed, make by-product and other impurity generated badly, and also it has high conversion rate, and more than or equal to 98% purity.

The invention relates to a method for producing high-purity miglitol. The method comprises the following stages that: Stage a. a miglitol producing strain is obtained through the cultivation of a culture medium consisting of D-sorbierite, a yeast extract and KH2PO4 and microfiltration separation; Stage b. the miglitol producing strain performs biotransformation, microfiltration, hyperfiltration, nanofiltration, and activated carbon decolorization to a substrate to obtain an intermediate of the miglitol; Stage c. hydrogenation reaction, ion fractionating, activated carbon decolorization, desorption, condensation and crystallization are performed to the intermediate of the miglitol obtained in the Stage b to obtain the high-purity miglitol. The adoption of the method can improve the production efficiency of the miglitol to the utmost extent, thereby realizing the industrialization of the high-purity miglitol.

The invention relates to a preparation method of a drug used for diabetes, namely Miglitol intermediate N-hydroxyethyl glucosamine. The preparation method is characterized in that glucose and ethanolamine are used as initial raw materials; with solvent, active nickel catalyst and amine compounds are used as catalysts for the catalytic hydrogenation; the reaction pressure and the temperature are controlled for the reaction; when the reaction is finished, N-hydroxyethyl glucosamine white crystals are obtained after post-processing and refining; the yield is larger than 90 percent, and the purity is larger than or equal to 98.5 percent (HPLC detection). The preparation method solves the problems of the prior art of high cost, harsh reaction conditions and complex preparing process caused by the adoption of dear metals (catalysts such as platinum, palladium-charcoal, etc.) with high catalytic activity for the catalytic hydrogenation.

Production of migneicohol is carried out by oxidizing for raw material, preparing 1-ethoxy-amino-1-deoxy-D-sorbic alcohol, coating ketogluconic acid oxide bacterium by polymerization ion film to prepare into micro-capsule containing bacterium, adding into 1-ethoxy-amino-1-deoxy-D-sorbic alcohol solution and micro-capsule containing bacterium into fermentor successively, agitating at 28-31degree, agitating, inducing into gas 1/1(V/V), converting for 23-28hrs, adjusting pH to 5.0-6.0, filtering out micro-capsule containing bacterium to obtain 1-ethoxy-amino-1-deoxy-D-sorbic alcohol filtrate, adding catalyst into filtrate, hydrogenating, refining for filtrate by resin, concentrating, and crystallizing to obtain the final product.

The invention discloses a distinguishing and determining method of entecavir chiral isomers. The method comprises the steps of adopting a chiral ligand, metal ions and the eight entecavir chiral isomers to form complexes with different stable forms; utilizing a mass-spectrography method for recognizing and distinguishing the complexes, wherein the chiral ligand comprises R-besifloxacin, beta-cyclodextrin, migltol or cefotaxime; the metal ions comprise alkaline-earth metals or transient state metals; the alkaline-earth metals comprise Mg and Ca; the transient state metals comprise Ni, Cu, Co, Zn and Mn. The method is fast, simple and convenient, overcomes the defects that a traditional HPLC method needs a specific chiral stationary phase, solvent gradient eluting consumed time is longer, and an enantiomeric separation degree is insufficient, and can be used for quickly distinguishing the eight entecavir chiral isomers and quantitatively determining.

The invention provides a pharmaceutical composition for improving complications of high-fat and high-sugar diet. The pharmaceutical composition comprises flavonoid and an alpha-glucosidase inhibitor, wherein the flavonoid is at least one selected from the group consisting of monomer baicalein, monomer chrysin, organic salts of the monomers and inorganic salts of the monomers, and the alpha-glucosidase inhibitor is one selected from the group consisting of monomer acarbose, monomer voglibose, monomer migltol, organic salts of the monomers and inorganic salts of the monomers. The composition provided by the invention can effectively reduce the dosage of the alpha-glucosidase inhibitor; desired effects can be obtained by mixing the flavonoid with the alpha-glucosidase inhibitor with a dosage 0.01 to 0.75 time of a normal dosage; the disadvantages of a great dosage and great side-effects in individual usage of the alpha-glucosidase inhibitor are overcome; the disadvantages of unobvious hypoglycemic effect, a great dosage, a long administration period and the like in individual usage of the flavonoid are overcome; and the disadvantages of complex components and difficult quality control of a traditional Chinese medicine compound drug are overcome.

The invention discloses a crystalline miglitol and a preparation method thereof. The technical contents related to the crystalline miglitol are not recorded in the existing literature. The miglitol crystal of the invention uses Cu-Ka radiation, and diffraction peaks are arranged at 14.1 degrees, 15.9 degrees, 19.5 degrees and 23.5 degrees of a powder X-ray diffraction spectrum which is embodied by a diffraction angle of 2 theta plus or abstract 0.2 degree. The crystalline miglitol has the advantages of low moisture absorption and being easy to purify except in the condition of high humidity; the crystalline miglitol which is excellent in stability is beneficial for the preparation of pharmaceutical preparation and improving bioavailability of drug.

The invention relates to a preparation method of miglitol intermediate, in particular to a preparation method of a derivative of N-substitution-1-deoxynojirimycin which is the key intermediate of miglitol. Gluoconobacter oxydans or the Gluoconobacter oxydans treated by immobilized cell technology are used repeatedly for transforming the substrate to the derivative of N-substitution-1-deoxynojirimycin which is the miglitol intermediate, the transfer temperature is controlled at 5 to 25 DEG C, pH value is controlled at 4.0 to 6.5 and dissolved oxygen is controlled at 5 to 80 percent (in volume). Adopting the invention can decrease the biotransformation cost, reduce the inter-assay of cell, and be suitable for the large scale industrial production, increase the mechanical strength of the wall of the strain prepared, make the strain not to dissolve during the cultivation in long-term liquid environment, lengthen the service life and have outstanding slow release performance.

The invention relates to a method for preparing miglitol intermediate N-hydroxyethyl glucosamine which is used for curing diabetes mellitus. The method is characterized by comprising the following steps: taking glucose and ethanolamine as raw materials, controlling reaction temperature and reaction environment in the presence of a solvent and a proper amount of dehydrating agent, carrying out a reaction with metal hydride, finishing the reaction, and obtaining white crystals of the droxyethyl glucosamine after aftertreatment and refining. Yield coefficient is more than 95% and purity is more than 99% (HPLC detection).

The invention provides a melbine/migltol hypoglycemic oral preparation composition and a preparation thereof. The weight ratio of the two main medicaments comprised in the composition is 2:3 to 200:1, preferably, 1:1 to 150:1. Except the main medicaments, the composition also can further comprises normal medicament auxiliary materials, such as an adhesive, a filling agent, a disintegrating agent, a lubricating agent, a flavoring agent, a wetting agent and a glidant. The prepared composition can be prepared into tablets, granules, capsules and sustained-release preparations by the common method, preferably, enteric-coated tablets, enteric-coated granules and enteric-coated capsules. The composition of the invention has the advantages of complementarity of action mechanisms of the main medicaments, multiple target points, good patient compliance and the like. The hypoglycemic oral preparation composition can be used for first-line treatment of type 2 diabetes, or can be used for second-line therapy under the condition that a melbine or sulfonylurea medicament cannot singly and effectively control the blood sugar.

The invention provides an oral medicament composition for treating diabetes and the complications of diabetes, belonging to the field of medicines. The oral medicament composition for treating diabetes and the complications of diabetes comprises migltol and heparin or low molecular heparin or a medicinal salt of the heparin or the low molecular heparin in the weight ratio of 1:0.1-9. The medicament composition plays a good synergic action on lowering blood sugar, can reduce the complications of diabetes and generate positive effect on the prognosis of a diabetic who takes the oral medicament composition for a long time so that the oral medicament composition for treating diabetes and the complications of diabetes is quite beneficial to the recovery of the diabetic.

The present invention relates to an oral blood-sugar-reducing compound medicinal preparation, which consists of an insulin sensitizer, a miglitol and auxiliary materials. Compared with the prior art, the present invention is characterized in that under a circumstance of a same curative effect, a separate dosage of the insulin sensitizer or the miglitol is reduced; at the same time compared with other hypoglycemic drugs, a side effect of the present invention is reduced; the insulin sensitizer and the miglitol have a synergistic effect: the insulin sensitizer and the miglitol respectively take curative actions towards a patient with hyperglycemia synchronously according to the different pharmacological effects and directly provide the patient or a doctor with a scientific combined medication to improve the curative effect and provide a clinic or the patient with convenience.

The present invention discloses a transforming bacterium strain and a method for catalytically synthesizing a miglitol intermediate. The transforming bacterium strain is obtained by transforming a recombinant expression plasmid pBBR-sldAB into a starting bacterium strain ZJB16009 and then conducing screening, and named as gluconobacter oxydans, has a strain number of pBBR-sldAB and a preservationnumber of CCTCC No.M2019033, is significantly higher in N-hydroxyethylglucosamine dehydrogenase activity than the starting bacterium strain ZJB16009, and also has a space-time yield about 2 times of the starting bacterium strain ZJB16009. The gluconobacter oxydans pBBR-sldAB has relatively high potential application value in catalytic synthesis of a key intermediate 6NSL of the miglitol.

The present invention discloses an application of miglitol to preparation of a medicine for treating cardiovascular diseases, and belongs to the technical field of medicines. The medicine is a medicament prepared from the miglitol as an active ingredient and a pharmaceutically acceptable excipient, and the obtained medicament has the remarkable treatment effect on the cardiovascular diseases caused by myocardial cell autophagy. Pharmacological tests show that the miglitol can obviously improve cardiac function injury and myocardial cell necrosis, improves the expression level of LC3 protein, and is suitable for being widely applied to treatment of the cardiovascular diseases.

The invention discloses pharmaceutical composition for treating or preventing obesity and metabolic syndrome and belongs to the field of pharmaceuticals. The pharmaceutical composition comprises active ingredients, namely orlistat and miglitol according to a preferable weight ratio of 1:0.1-100, and a more preferable weight ratio of 1:0.5-10. The pharmaceutical composition can be made into conventional pharmaceutical dosage forms, preferably the solid form. The pharmaceutical composition has evident synergistic effect on treating or preventing obesity and metabolic syndrome, is capable of lowering the risks of cardiovascular diseases and has broad medical application prospect.